Jodi Maple-Grødem, PhD
Area of Focus
- GBA1
- Cohort
- Dementia
- Collaboration
- Education
Biography
I completed my training as a molecular biologist at the Universities of Edinburgh and Leicester in the UK and am now part of the team at the Centre for Movement Disorders in Stavanger, Norway.
I feel fortunate to collaborate on projects involving renowned, long-running population-based studies of incident Parkinson’s disease, where our focus is on understanding the natural history of the disease and identifying clinical and biological markers. One of my main areas of interest lies in exploring the implications of glucocerebrosidase (GCase) dysfunction and mutations in the GCase gene (GBA1) on disease risk and progression.
I lead the ProLBD study, a 10-year prospective longitudinal cohort investigation, aimed at contributing to early detection, prognosis, and biomarker identification for prodromal Lewy Body Diseases. Additionally, I contribute to the ANeED clinical trials team, where we evaluate Ambroxol’s tolerability, safety, and effects in patients with Dementia with Lewy bodies.